The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
The CRISPR‐Cas13a Gene‐Editing System Induces Collateral Cleavage of RNA in Glioma Cells
Open accessAbstract
RNA is rarely used as a therapeutic target due to its flexible structure and instability. CRISPR‐Cas13a is a powerful tool for RNA knockdown, and the potential application of CRISPR‐Cas13a in cancer cells should be further studied. In this study, overexpression of LwCas13a by lentivirus in glioma cells reveals that crRNA‐EGFP induces a “collateral effect” after knocking down the target gene in EGFP‐expressing cells. EGFRvIII is a unique EGFR mutant subtype in glioma, and the CRISPR‐Cas13a system induces death in EGFRvIII‐overexpressing glioma cells. Bulk and single‐cell RNA sequencing analysis in U87‐Cas13a‐EGFRvIII cells confirm the collateral effect of the CRISPR‐Cas13a system. Furthermore, CRISPR‐Cas13a inhibits the formation of glioma intracranial tumors in mice. The results demonstrate the collateral effect of the CRISPR‐Cas13a system in cancer cells and the powerful tumor‐eliminating potential of this system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
RNA targeting with CRISPR–Cas13
Abudayyeh, O. O., Gootenberg, J. S., Essletzbichler, P., Han, S., Joung, J., Belanto, J. J., Verdine, V., Cox, D. B. T., Kellner, M. J., Regev, A., et al. (2017) · Nature · doi:10.1038/nature24049 · Cited by 2,093
Cited by
Glia-to-Neuron Conversion by CRISPR-CasRx Alleviates Symptoms of Neurological Disease in Mice
Zhou, H., Su, J., Hu, X., Zhou, C., Li, H., Chen, Z., Xiao, Q., Wang, B., Wu, W., Sun, Y., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.024 · Cited by 437
Nguyen, L. T., Smith, B. M., & Jain, P. K. (2020) · Nature Communications · doi:10.1038/s41467-020-18615-1 · Cited by 435
Programmable RNA editing with compact CRISPR–Cas13 systems from uncultivated microbes
Xu, C., Zhou, Y., Xiao, Q., He, B., Geng, G., Wang, Z., Cao, B., Dong, X., Bai, W., Wang, Y., et al. (2021) · Nature Methods · doi:10.1038/s41592-021-01124-4 · Cited by 351
Feng, W., Newbigging, A. M., Tao, J., Cao, Y., Peng, H., Le, C., Wu, J., Pang, B., Li, J., Tyrrell, D. L., et al. (2021) · Chemical Science · doi:10.1039/d0sc06973f · Cited by 312
Programmable RNA targeting with the single-protein CRISPR effector Cas7-11
Özcan, A., Krajeski, R., Ioannidi, E., Lee, B., Gardner, A., Makarova, K. S., Koonin, E. V., Abudayyeh, O. O., & Gootenberg, J. S. (2021) · Nature · doi:10.1038/s41586-021-03886-5 · Cited by 263
Zhou, T., Huang, R., Huang, M., Shen, J., Shan, Y., & Xing, D. (2020) · Advanced Science · doi:10.1002/advs.201903661 · Cited by 292
CRISPR technologies for genome, epigenome and transcriptome editing
Villiger, L., Joung, J., Koblan, L., Weissman, J., Abudayyeh, O. O., & Gootenberg, J. S. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00697-6 · Cited by 256
High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects
Tong, H., Huang, J., Xiao, Q., He, B., Dong, X., Liu, Y., Yang, X., Han, D., Wang, Z., Wang, X., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01419-7 · Cited by 230
Self-citationKelley, C. P., Haerle, M. C., & Wang, E. T. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111226 · Cited by 61
The double life of CRISPR–Cas13
Bot, J. F., van der Oost, J., & Geijsen, N. (2022) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2022.102789 · Cited by 50
Structural basis for the activation of a compact CRISPR-Cas13 nuclease
Deng, X., Osikpa, E., Yang, J., Oladeji, S. J., Smith, J., Gao, X., & Gao, Y. (2023) · Nature Communications · doi:10.1038/s41467-023-41501-5 · Cited by 35
Intrinsic targeting of host RNA by Cas13 constrains its utility
Li, Z., Li, Z., Cheng, X., Wang, S., Wang, X., Ma, S., Lu, Z., Zhang, H., Zhao, W., Chen, Z., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01109-y · Cited by 31
RNA-guided cell targeting with CRISPR/RfxCas13d collateral activity in human cells
Shi, P., Murphy, M. R., Aparicio, A. O., Kesner, J. S., Fang, Z., Chen, Z., Trehan, A., & Wu, X. (2021) · doi:10.1101/2021.11.30.470032 · Cited by 21
Collateral cleavage of 28s rRNA by RfxCas13d causes death of mice
Li, Y., Xu, J., Guo, X., Li, Z., Cao, L., Liu, S., Guo, Y., Wang, G., Luo, Y., Zhang, Z., et al. (2022) · doi:10.1101/2022.01.17.476700 · Cited by 12
Self-citationSynthetic Type III-E CRISPR-Cas Effectors for Programmable RNA-targeting
Brogan, D. J., Lin, C. P., Benetta, E. D., Wang, T., Chen, F., Li, H., Lin, C., Komives, E. A., & Akbari, O. S. (2026) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169566 · Cited by 4
Metadata
- Authors
- Wang, Q., Liu, X., Zhou, J., Yang, C., Wang, G., Tan, Y., Wu, Y., Zhang, S., Yi, K., & Kang, C.
- Venue
- Advanced Science
- Publisher
- Wiley
- Published
- 2019-08-29
- Volume
- 6
- Issue
- 20
- Pages
- 1901299-1901299
- ISSN
- 2198-3844 (ISSN-L)
- OpenAlex
- W2970054604
- Cited by
- 162
- References
- 4
- FWCI
- 4.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.